Obesity Clinical Trial
Official title:
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
The purpose of this pilot study is to conduct a 12-week pilot feasibility study testing usability of the adapt learning tool (AdaptRL)in a weight loss intervention (ADAPT study). Building upon a previous just-in-time adaptive intervention (JITAI), a reinforcement learning tool will generate decision rules regarding which behavior change techniques, in which contexts, are most efficacious for promoting weight loss in a sample of 20 adults.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Age 18-55 years 2. Body Mass Index of 25-40 kg/m2 3. Not adhering to the US physical activity guidelines of at least 150 moderate-to-vigorous intensity activity minutes/week 4. English-speaking and writing 5. No pre-existing medical condition(s) that preclude adherence to an unsupervised exercise program, diabetes treated with insulin, history of heart attack or stroke, current treatment for cancer, or inability to walk for exercise 6. Has a smartphone with a data and text messaging plan Exclusion Criteria: 1. Current participation in another weight loss, physical activity, nutrition program, or research study 2. Currently taking weight loss medications 3. Currently pregnant or planning pregnancy in the next 3 months 4. Lost 10 or more pounds and kept it off in the last 6 months 5. History of weight loss surgery 6. Report a heart condition, chest pain during periods of activity or rest, loss of consciousness, joint or bone problems, medical conditions that could limit exercise, or prescription medicine used for blood pressure or heart condition on the Physical Activity Readiness Questionnaire (PAR-Q) 7. Type 1 diabetes or currently receiving medical treatment for Type 2 diabetes 8. Cancer treatment within the past 5 years 9. Tuberculosis 10. Health or psychological diagnoses that preclude participation in a prescribed dietary and exercise program, including diagnosis of schizophrenia or bipolar disorder, hospitalization for a psychiatric diagnosis in the past year, a diagnosis of alcohol or substance abuse 11. Report a past diagnosis of or receiving treatment for The Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) eating disorder (anorexia nervosa or bulimia nervosa). 12. Moving out of the area in the next 4 months 13. Out of town for a week or more during the study period 14. Another member of the household is a participant or staff member in this trial 15. Not willing to attend two study visits 16. Not willing to wear a Fitbit every day |
Country | Name | City | State |
---|---|---|---|
United States | University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
UNC Lineberger Comprehensive Cancer Center | Duke University, National Cancer Institute (NCI), RTI International |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility (success of using the AdaptRL Tool) | Feasibility as the success of using the AdaptRL Tool will be defined as the mean number of messages delivered per participant per day. | up to 12 weeks | |
Primary | Study engagement | Study engagement will be defined as the percent of person-days in which participants accessed the web app. | up to 12 weeks | |
Primary | Self-monitoring adherence | Self-monitoring adherence will be defined as the percent of person-days in which participants tracked at least one weight loss behavior (tracked calories, wore tracker, or self-weighed). | up to 12 weeks | |
Secondary | Message satisfaction | Message satisfaction will be defined as the percent of delivered messages that were rated as "liked" (compared to dislike or not rated). | up to 12 weeks | |
Secondary | Percent weight loss | Percent weight loss will be defined as weight change from baseline to 12 weeks calculated as a percent from baseline weight. | 12 weeks | |
Secondary | Moderate-to-vigorous physical activity | Moderate-to-vigorous physical activity will be defined as the change in self-reported weekly minutes of moderate-to-vigorous physical activity as measured by the Paffenbarger Activity Questionnaire from baseline to 12 weeks. The minimum is 0, no maximum. Higher numbers represent higher minutes of weekly moderate-to-vigorous physical activity. | Baseline, 12 weeks | |
Secondary | Dietary intake | Dietary intake will be defined as the change in average daily calorie intake as measured by the Automated Self-Administered 24-hour (ASA 24-hour) dietary recalls from baseline to 12 weeks. Daily caloric intake is measured in kcals, with higher numbers indicating higher caloric intake. | Baseline, 12 weeks | |
Secondary | Adherence to calorie goal | Adherence to the calorie goal as the percent of person-days in which participants tracked their calories and stayed at or under their calorie goal will be measured by dietary self-monitoring data tracked in the Fitbit app and transmitted via Application Programming Interface (API) to study servers. | up to 12 weeks | |
Secondary | Adherence to daily active minutes goal | Adherence to daily active minutes goal, the percent of person-days in which participants met their daily active minute goal, will be measured by activity tracker data tracked in the Fitbit app and transmitted via Application Programming Interface (API) to study servers. | up to 12 weeks | |
Secondary | Adherence to daily self-weighing | Adherence to daily self-weighing, the percent of person-days in which participants self-weighed will be measured by Fitbit smart scales and transmitted via Application Programming Interface (API) to study servers. | up to 12 weeks | |
Secondary | Adherence to daily self-weighing at the participant-day level | Adherence to daily self-weighing at the participant-day level, the percent of person-days weighed after the message randomization time until the end of the day will be measured by Fitbit smart scales and transmitted via Application Programming Interface (API) to study servers. | up to 12 weeks | |
Secondary | Adherence to the daily self-weighing percent of person-days weighed | Adherence to the daily self-weighing percent of person-days weighed the day after the message randomization will be measured by Fitbit smart scales and transmitted via Application Programming Interface (API) to study servers. | up to 12 weeks | |
Secondary | Achievement of active minutes goal | Achievement of active minutes goal, percent of person-days met active minutes goal after the message randomization time until the end of the day will be measured by activity tracker data tracked in the Fitbit app and transmitted via Application Programming Interface (API) to study servers. | up to 12 weeks | |
Secondary | Achievement of active minutes goal percent of person-days | Achievement of active minutes goal percent of person-days met active minutes goal the day after the message randomization will be measured by activity tracker data tracked in the Fitbit app and transmitted via Application Programming Interface (API) to study servers. | up to 12 weeks | |
Secondary | Achievement of calorie goal (at or under goal) | Achievement of calorie goal (at or under goal) percent of person-days met calorie goal after the message randomization time until the end of the day will be measured by dietary self-monitoring data tracked in the Fitbit app and transmitted via Application Programming Interface (API) to study servers. | up to 12 weeks | |
Secondary | Achievement of calorie goal (at or under goal) percent of person-days | Achievement of calorie goal (at or under goal) percent of person-days met calorie goal the day after the message randomization will be measured by dietary self-monitoring data tracked in the Fitbit app and transmitted via Application Programming Interface (API) to study servers. | up to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |